Results 251 to 260 of about 849,024 (375)

Risk factors for acute non-A, non-B hepatitis and their relationship to antibodies for hepatitis C virus: a case-control study. [PDF]

, 1994
Andrea Mele, Luciano Sagliocca, G Manzillo, Fabio Converti, P Amoroso, M. A. Stazi, Luigina Ferrigno, M. Rapicetta, Elisabetta Franco, B Adamo   +9 more
openalex   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Prevalence of hepatitis C virus infection in Qatar's resident population based on a national screening campaign. [PDF]

Sci Rep
Al-Romaihi HE, El-Khoury R, Himatt S, Derbala MFM, Idries AM, Saeed A, Abdelmageed MK, Elawad KH, Alex M, Sallam M, Al-Shamali MH, Coyle P, Alkaabi S, Chemaitelly H, Bansal D, Abu-Raddad LJ.   +15 more
europepmc   +1 more source

Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR [PDF]

, 1994
Nathalie Besnard, Patrice André
openalex   +1 more source

Advances in Isotope Labeling for Solution Nucleic Acid Nuclear Magnetic Resonance Spectroscopy

ChemPlusChem, EarlyView.
Recent advances in the field of nucleic acid nuclear magnetic resonance (NMR) are presented. Stable isotope labeling protocols and new approaches to segmentally label nucleic acid with NMR‐active residues are summarized. The novel methods will have a strong impact on the future of nucleic acid NMR and the characterization of structure and dynamics of ...
Stefan Hilber, Solomon Kojo Attionu, Theodore Kwaku Dayie, Christoph Kreutz   +3 more
wiley   +1 more source

TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk

Hepatology, EarlyView., 2022
The systematic approach in elucidating the gain‐of‐function (GOF) roles of TP53 mutations in early liver carcinogenesis. Unique downstream targets of TP53 L3 mutations were identified from chormatin immunoprecipitation sequencing in HCC cell lines, followed by a series of validation assays to substantiate the exclusive transcriptional regulations ...
Yin Kau Lam, Jianqing Yu, Hao Huang, Xiaofan Ding, Alissa M. Wong, Howard H. Leung, Anthony W. Chan, Kelvin K. Ng, Mingjing Xu, Xin Wang, Nathalie Wong   +10 more
wiley   +1 more source

The global prevalence of co-occurrence of Sjögren syndrome and Hepatitis C virus infection: A systematic review and meta-analysis. [PDF]

Virus Res
Arefinia N, Askarpour H, Ghoreshi ZA, Mashayekhi-Sardoo H, Ali-Hassanzadeh M.   +4 more
europepmc   +1 more source

Hepatitis C virus and hepatocellualr carcinoma [PDF]

, 1994
Michael C. Kew
openalex   +1 more source

Populations Addressed in Vaccines Approved via the European Medicines Agency

Clinical Pharmacology &Therapeutics, EarlyView.
Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf, Lukas Westphal, Jonathan Kimmelman, Christine E. Hallgreen   +3 more
wiley   +1 more source